Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)
ConditionWilms Tumor
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-17
SponsorCentre Oscar Lambret
About this trial
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Eligibility criteria
Qualifiers
Patient ≥18 months old and ≤ 17 years old
Relapsed or refractory Wilms tumor, histologically proven at diagnosis
After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for which there would not be any curative therapy. If 1 line for high risk relapse, the enrolment should be confirmed by coordinators.
Radiologically measurable or evaluable disease (visible, target or non-target-lesion on MRI or CT-scan)
Disqualifiers
Prior history of other cancer within 5 years
Chemotherapy or radiotherapy of target lesion within 3 weeks prior to inclusion
Target therapy within less than 5 * half-life of the substance prior to inclusion
Major surgery within 15 days prior to inclusion
Trial design
Treatments tested in this trial
- Vincristine
- Irinotecan
- Temozolomide
- Etoposide
- Cis-Retinoic acid
Treatment groups
28 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov